Merck (MRK) Doing Well, But Becoming More Transparent

Merck (NYSE: MRK) stock has been doing well recently. However, all is not well with the Pharma giant.

According to CNBC correspondent Mike Huckman, Merck is now moving towards becoming more transparent. Merck recently acquired Schering-Plough. In a surprising move, officials at Merck gave a no-go verdict for an experimental HIV/AIDS drug, which itacqui red from Schering-Plough. The company had earlier announced that it was on track to file for FDA approval. According to a company release, the HIV drug Vicriviroc failed two late-stage trials. The company had earlier estimated a peak sale of $500 million to $750 million for the drug post-approval.